These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Bonnet M; Fleury J; Guenoun S; Yaniali A; Dumas C; Hajjar C Graefes Arch Clin Exp Ophthalmol; 1996 Dec; 234(12):739-43. PubMed ID: 8986445 [TBL] [Abstract][Full Text] [Related]
26. Postoperative aqueous humour flare as a surrogate marker for proliferative vitreoretinopathy development. Mulder VC; van Dijk EHC; van Meurs IA; La Heij EC; van Meurs JC Acta Ophthalmol; 2018 Mar; 96(2):192-196. PubMed ID: 29068530 [TBL] [Abstract][Full Text] [Related]
27. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. La Heij EC; van de Waarenburg MP; Blaauwgeers HG; Kessels AG; Liem AT; Theunissen C; Steinbusch H; Hendrikse F Am J Ophthalmol; 2002 Sep; 134(3):367-75. PubMed ID: 12208248 [TBL] [Abstract][Full Text] [Related]
28. Validity of aqueous flare measurement in predicting proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. Conart JB; Kurun S; Ameloot F; Tréchot F; Leroy B; Berrod JP Acta Ophthalmol; 2017 Jun; 95(4):e278-e283. PubMed ID: 27682827 [TBL] [Abstract][Full Text] [Related]
29. Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: correlations with extent, duration of RRD and PVR grade. Symeonidis C; Papakonstantinou E; Androudi S; Georgalas I; Rotsos T; Karakiulakis G; Diza E; Dimitrakos SA Cytokine; 2014 Jun; 67(2):71-6. PubMed ID: 24725542 [TBL] [Abstract][Full Text] [Related]
30. Comparative study of incomplete posterior vitreous detachment as a risk factor for proliferative vitreoretinopathy. Capeans C; Lorenzo J; Santos L; Suarez A; Copena MJ; Blanco MJ; Sánchez-Salorio M Graefes Arch Clin Exp Ophthalmol; 1998 Jul; 236(7):481-5. PubMed ID: 9672792 [TBL] [Abstract][Full Text] [Related]
31. Levels of pentosidine in the vitreous of eyes with proliferative diabetic retinopathy, proliferative vitreoretinopathy and retinal detachment. Tomé CC; De Rojas Silva MV; Rodríguez-García J; Rodríguez-Segade S; Sánchez-Salorio M Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1272-6. PubMed ID: 15947940 [TBL] [Abstract][Full Text] [Related]
32. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy. Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J Am J Ophthalmol; 1999 Dec; 128(6):763-5. PubMed ID: 10612518 [TBL] [Abstract][Full Text] [Related]
33. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy. Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976 [TBL] [Abstract][Full Text] [Related]
34. [Postoperative proliferative vitreoretinopathy in rhegmatogenous retinal detachment associated with stage B preoperative proliferative vitreoretinopathy: comparative results of trans-scleral retinopexy with diode laser or trans-pupillary retinopexy with argon laser]. Duquesne N; Fleury J; Bonnet M J Fr Ophtalmol; 1998 Oct; 21(8):555-9. PubMed ID: 9833220 [TBL] [Abstract][Full Text] [Related]
35. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Kon CH; Asaria RH; Occleston NL; Khaw PT; Aylward GW Br J Ophthalmol; 2000 May; 84(5):506-11. PubMed ID: 10781515 [TBL] [Abstract][Full Text] [Related]
36. Levels of Anti-Retinal Antibodies in Retinal Detachment and Proliferative Vitreoretinopathy. Ichinohasama R; Nishiguchi KM; Fujita K; Aizawa N; Inoue T; Sasaki E; Kunikata H; Nakazawa T Curr Eye Res; 2018 Jun; 43(6):804-809. PubMed ID: 29547015 [TBL] [Abstract][Full Text] [Related]
37. [Vitrectomy in proliferative vitreoretinopathy. Anatomical and functional results in 501 patients]. Körner F; Böhnke M Klin Monbl Augenheilkd; 1995 Apr; 206(4):239-45. PubMed ID: 7791283 [TBL] [Abstract][Full Text] [Related]
38. Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis. Li M; Li H; Jiang P; Liu X; Xu D; Wang F Mol Biosyst; 2014 May; 10(5):1055-62. PubMed ID: 24556753 [TBL] [Abstract][Full Text] [Related]
39. Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Barile GR; Chang SS; Park LS; Reppucci VS; Schiff WM; Schmidt AM Curr Eye Res; 1999 Sep; 19(3):219-27. PubMed ID: 10487959 [TBL] [Abstract][Full Text] [Related]
40. Upregulation of RAGE and its ligands in proliferative retinal disease. Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]